Restoring health in critically ill patients suffering of severe infections
The unique therapeutic approach of CAL02 consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections.
CAL02 is a phase 2-stage drug that has successfully been tested in ICU patients with severe community-acquired pneumonia.
Combioxin’s Latest news
Combioxin receives positive feedback from FDA on its pre-investigational new drug (PIND) application for use of CAL02 in COVID-19 patients at risk of severe bacterial infections.
May 4, 2020